Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease.

在预防莱姆病的疫苗范围内开发 INI-4001 和 INI-2002 佐剂。

• 批准号: 10667372
• 负责人: JAY EVANS
• 金额: $ 100万
• 依托单位: UNIVERSITY OF MONTANA
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2024-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10667372
• 关键词: Adjuvant; Affect; Agonist; American; Bacteriophages; Bite; Borrelia burgdorferi; Capsid Proteins; Chronic; Contractor; Development; Formulation; Health; Human; Ixodes; Lipoproteins; Lyme Arthritis; Lyme Disease; Lyme Disease Encephalopathy; Lyme Disease Vaccines; Modeling; Mus; Route; TLR4 gene; TLR7 gene; Ticks; Vaccination; Vaccine Adjuvant; Vaccine Antigen; Vaccines; Virion; efficacy study; immunogenicity; novel; prevent; skin disorder; transmission process

Lyme disease, caused by the bite of Borrelia burgdorferi-infect Ixodes ticks, affects close to half a million Americans each year and can cause serious, long term, chronic health issues such as Lyme arthritis, Lyme encephalopathy, or skin disorders. No human vaccine is currently available and the contractor proposes to develop a novel subunit Lyme disease vaccine adjuvanted with a combination adjuvant composed of two synthetic TLR agonists (TLR4 and TLR7/8).

莱姆病是由感染伯氏疏螺旋体的硬蜱叮咬引起的，每年影响近50万美国人，并可能导致严重的、长期的慢性健康问题，如莱姆关节炎、莱姆脑病或皮肤病。目前尚无人类疫苗可用，承包商提议开发一种新型莱姆病亚单位疫苗，该疫苗辅以由两种合成TLR激动剂(TLR4和TLR7/8)组成的复合佐剂。